Kornimate/medical-research-clean huggingface dataset:
understanding barriers to initiation and adherence to endocrine therapy in young breast cancer survivors of diverse backgrounds

Conditions: Breast Cancer

Summary: the overall goal of this study is to qualitatively explore how behavioral, cultural, psychosocial, and economic barriers and facilitators affect the decision to start and adhere to endocrine therapy (et) among young breast cancer survivors of diverse racial, ethnic, and socio-economic backgrounds with hormone receptor positive (hr+) breast cancer

a qualitative study that will use interviews to gain an in depth understanding of factors affecting the decision to start and adhere to endocrine therapy (et) among young breast cancer survivors of diverse racial, ethnic, and socio-economic backgrounds with hormone receptor positive (hr+) breast cancer

Eligibility criteria:
inclusion criteria: * are hispanic, latina, black, or identify as socio-economically disadvantaged (any racial/ethnic background) as measured by an item of financial distress answering that they are "having difficulty paying the bills no matter what they do" to a question about their current household financial situation.18, 19 * report a history of stage 1-3 breast cancer * reports hr+ breast cancer and confirm that they have had a discussion with their doctor about adjuvant et; or indicate that they are taking et, even if they do not know their hr status, answer they are hr-, or do not recall having a discussion about et) * not in active treatment (e.g., chemotherapy, radiation), with the exception of herceptin * at least 3 months, but no more than 3 years out of completion of active treatment * no evidence of recurrent/metastatic disease * at least 18, but\< 45 years of age at diagnosis of first invasive breast cancer * english or spanish speaking * are willing to consent to the interview exclusion criteria: * hr- breast cancer and indicate they are not taking et * hr+ breast cancer but do not confirm discussion of et or indicate they are taking et * stage 0 (dcis) breast cancer * recurrent or metastatic disease * less than 3 months or more than 3 years post-active treatment * less than 18 years old or ≥45 years old at diagnosis

Keywords: breast cancer
safety and efficacy of the inspiromatic inhaler in comparison to the aerolizer inhaler when delivering formoterol

Conditions: Asthma

Summary: double-blind study, randomized, controlled, and crossover. study recruited 30 volunteers with stable asthma aged 8-18 years. participants will perform lung function as part of the routine follow-up then will receive a foradil 12mcg either with an aerolizer (a standard dry powder inhaler) or with the inspiromatic (an active, breath synchronized innovative inhaler). 3-60 days later participants will receive the same drug through the other inhaler. pre and post treatment (15 min, 30 min, 60 min) lung function results, drug levels in the blood, vital signs and side effects will be recorded.


Eligibility criteria:
inclusion criteria: * children 8-18 years with asthma * 50\<fev1\<80 * can perform spirometry exclusion criteria: * poor cooperation * pregnancy * milk allergy * other lung disease * prior familiarity with aerolizer

Keywords: asthma dry powder inhaler
study to compare an oral weekly islatravir/lenacapavir regimen with bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed people with hiv-1

Conditions: HIV-1-infection

Summary: the goal of this clinical study is to learn about the safety and efficacy of switching to once weekly tablet of islatravir/lenacapavir (isl/len) regimen versus continuing standard treatment of bictegravir/emtricitabine/tenofovir alafenamide (b/f/taf) in people with human immunodeficiency virus (pwh) who are virologically suppressed (hiv-1 rna levels \< 50 copies/ml) on b/f/taf for ≥ 6 months prior to screening. the primary objective is to evaluate the efficacy of switching to oral weekly isl/len tablet regimen versus continuing b/f/taf in virologically suppressed pwh at week 48.


Eligibility criteria:
key inclusion criteria: * hiv-1 rna \< 50 copies/ml for ≥ 6 months before screening, as documented by: 1. one hiv-1 rna \< 50 copies/ml immediately preceding the 24 week period prior to screening. 2. within 24 weeks prior to screening, if hiv-1 rna results are available, all levels must be \< 50 copies/ml. 3. during the 6 to 12 months period prior to screening, transient detectable viremia ≥ 50 copies/ml is acceptable ("blip"), as long as it is not confirmed on 2 consecutive visits. * plasma hiv-1 rna levels \< 50 copies/ml at screening. * individuals are receiving b/f/taf for ≥ 6 months prior to screening and willing to continue until day 1. * individuals assigned female at birth and of childbearing potential who engage in heterosexual intercourse must agree to use protocol-specified methods of contraception. key exclusion criteria: * prior virologic failure. * prior use of, or exposure to isl or len. * active, serious infections requiring parenteral therapy within 30 days before randomization. * active tuberculosis infection. * acute hepatitis within 30 days before randomization. * hepatitis b virus (hbv) infection as determined below at the screening visit: 1. positive hbv surface antigen or 2. positive hbv core antibody and negative hbv surface antibody. note: individuals found to be susceptible to hbv infection (eg negative hepatitis b surface antibody at the screening visit, regardless of prior hbv vaccination history) should be recommended to receive hbv vaccination. * active hepatitis c virus (hcv) coinfection, defined as detectable hcv rna. note: individuals with prior/inactive hcv infection (defined as undetectable hcv rna) may be enrolled. * any of the following laboratory values at screening: 1. creatinine clearance (clcr) ≤ 30 ml/min according to the cockcroft-gault formula 2. alanine aminotransferase \> 5 x upper limit of normal (uln) 3. direct bilirubin \> 1.5 x uln 4. platelets \< 50,000/μl 5. hemoglobin \< 8.0 g/dl note: other protocol defined inclusion/exclusion criteria may apply.
trial of music during labor and delivery

Conditions: Labor Pain

Summary: the use of music is widely supported in various areas of medicine: first of all in the psychiatric field as in the treatment of autism in children, obtaining surprising results even on alzheimer's patients, or the unparalleled effect of music on those suffering from depression. to strengthen the thesis of the usefulness of music in medicine there is what is called pnei, or the psychoneuroendocrinoimmunology. this discipline consists in the study of mutual interactions between mental activity, behavior, nervous system, endocrine system and immune reactivity. the pnei itself no longer pays attention to the mind with respect to the body, but using the principles of the empirical epistemology of the scientific method strives to clarify those connections that make the nervous system, mind, immunity and hormonal regulation a unique and complex homeostatic control system of the individual, whose synergism would be able to modify certain biological behaviors, such as the transition from a distress to an eustress. this passage would seem to be of particular obstetric interest going to significantly change the course of labor in terms of pain, anxiety and well-being of women. in fact, many women prefer not to resort to partoanalgesia and famaci for pain control during labor. a recent cochrane review analyzed the effectiveness of music in the control of pain in labor, confirming its role in this sense. however, he concluded that the quality of available evidence varied from low to very low, thus highlighting the need for further studies in this area. thus, the present study arises with the rational to satisfy this need for further investigation into the positive effects of music on pain in women in labor.


Eligibility criteria:
inclusion criteria: * singleton gestations; * term of phisiological pregnancy * spontaneous labor * diagnosis of active phase of labor; * nulliparous between 37 and 42 gestation weeks with cephalic presentation ; * maternal age between 18 and 45 years. exclusion criteria: * multiple gestations; * preterm labor; * preterm premature rupture of membranes * induction to delivery labor; * hipertensive disorders; * fetal abnormalities; * diabetes mellitus; * intrauterine growth retardation; * post-term pregnancy; * multiple vaginal delivery; * women with an altered state of consciousness, severely ill, mentally disabled; * women who are unconscious, severly ill, mentally handicapped; * women under the age of 18 years or over the age of 45 years.
effect of the use of low intensity therapeutic laser

Conditions: Wound; Diabetic Foot; LTBI

Summary: diabetes mellitus consists of a heterogeneous group of metabolic disorders that have hyperglycemia in common, resulting from defects in insulin action, insulin secretion, or both. diabetes mellitus has gained increasing importance and is considered one of the main themes of global health problems due to the damage caused to quality of life, public health and the epidemiological picture presented. among the complications are diabetic foot ulcers, with higher prevalence in the lower limbs, they are classified as loss of skin continuity, which can reach from the epidermis to deep structures such as muscles, bones and tendons.

100 volunteers will be recruited and the research will be carried out through the integrated center of medical specialties (ciem) - polyclinic, through referral from the specialist in vascular surgery after a thorough examination of the feet. volunteers of both sexes, aged over 18 years, dm and diabetic ulcers will be admitted. volunteers who present any autoimmune disease, concomitant psychiatric disorders or contraindications to the treatment methods adopted by the research will be excluded. inclusion in the study will take place after signing the informed consent forms, after approval by the ethics committee.

Eligibility criteria:
inclusion criteria: * type 2 diabetes mellitus patients with diabetic foot ulcers; * patients aged 18 and over. exclusion criteria: * patients with autoimmune diseases * patients with concomitant psychiatric disorders * patients with contraindications to treatment methods * patients with infected diabetic foot ulcers.

Keywords: diabetes mellitus low-level light therapy diabetic foot
symptomatic remission and social function in participants treated with paliperidone extended release (er)

Conditions: Schizophrenia

Summary: the purpose of this study is to explore the relationship between achieving symptomatic remission status by means of the 8 items of positive and negative syndrome scale (panss), and personal and social functioning by means of the personal and social performance (psp) scale in participants treated with flexibly dosed paliperidone er.

this is an open label (all people know the identity of the intervention), multicenter (when more than one hospital or medical school team work on a medical research study) and prospective (study following participants forward in time) 12-week study. participants can be either in- or outpatients. the total study duration will be 12 weeks for each participant and will include following visits: screening, week 0, 4, 8, and 12 (end of treatment or early withdrawal). throughout the study, participants will receive paliperidone er in a flexible dosing range of 3 to 12 milligram per day (mg/day). efficacy will primarily be evaluated by panss and psp scale. participants' safety will also be monitored throughout the study.

Eligibility criteria:
inclusion criteria: * participants who meet the diagnostic and statistical manual of mental disorders, 4th edition (dsm-iv) criteria for schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations, and withdrawal into the self) * participant is drug naive or participant's previous treatment is considered unsuccessful due to one or more of the following reasons: lack of efficacy, lack of tolerability or safety, lack of compliance and/or other reasons * participants or their legally acceptable representatives had signed an informed consent document indicating that they understand the purpose of and procedures required for the study and were willing to participate in the study * women must be postmenopausal for at least 1 year, surgically sterile, abstinent, or, if sexually active, agree to practice an effective method of birth control before entry and throughout the study and must have a negative urine pregnancy test at screening exclusion criteria: * participants with use of clozapine, paliperidone extended release (er), any conventional depot neuroleptic or risperdal consta during the last 3 months * participants with serious unstable medical condition, including known clinically relevant laboratory abnormalities * participants with history of neuroleptic malignant syndrome (high fever, rigid muscles, shaking, confusion, sweating more than usual, increased heart rate or blood pressure, or muscle pain or weakness) * participants with known hypersensitivity to paliperidone er or risperidone * participants with inability to swallow the whole study medication tablet with aid of water

Keywords: schizophrenia paliperidone extended release
a randomized, double-blind, active control trial comparing effects of telmisartan, candesartan and amlodipine, alone or plus metformin, on non-diabetic, obese hypertensive patients

Conditions: Hypertension; Obesity

Summary: the epidemic of obesity is associated with a considerable rise in the incidence of the metabolic syndrome, type 2 diabetes mellitus, and hypertension. insulin resistance plays an important role in the pathogenesis of obesity related hypertension. these patients are at high risk to suffer from cardiovascular events. however, current guidelines for treatment of hypertension do not provide specific recommendation for the pharmacotherapy of obese hypertensive patients due to lack of prospective randomized intervention studies in non-diabetic obese hypertensive patients. aside from their antihypertensive effects, angiotensin ii receptor blockers (arb) were shown to improve insulin sensitivity. furthermore, metformin is commonly used to treat the obese type 2 diabetes mellitus. metformin can also lower body weight and increase insulin sensitivity. in a prospective, double-blind, double-dummy, randomized, parallel-group study, we will evaluate the effects of arb (telmisartan and candesartan) or amlodipine combination with metformin on weight gain, visceral fat, and metabolic parameters in obese hypertensive patients without diabetes mellitus compared with obese hypertensives on arb or amlodipine treatment alone. this study will help to develop future comprehensive treatment strategies and guidelines for obesity related hypertension.


Eligibility criteria:
inclusion criteria: * grade 1 or 2 hypertension: 140mmhg≤sbp\<180mmhg, and/or 90mmhg≤dbp\<110mmhg * waist circumference higher than 90cm in men, 80cm in women exclusion criteria: * diabetes * grade 3 hypertension: sbp≥180mmhg, or dbp≥110mmhg * known allergy or hypersensitivity to trial drugs * myocardial infarction or cerebrovascular accident in the year preceding the trial * clinical congestive heart failure * history of hepatitis or cirrhosis * history of kidney disease

Keywords: hypertension abdominal obesity treatment
versius or laparoscopic abdominal hernia repair

Conditions: Abdominal Hernia; Abdominal Surgery

Summary: this trial will compare laparoscopic and robotic-assisted abdominal hernia repairs, using the versius® system. we will initially aim to recruit 60 patients (20 patients in the laparoscopic arm and 40 in the robotic arm) in order to assess the ergonomic impact of each modality on the operating surgeon. this aims to provide in vivo information on whether robotic surgery provides any advantages to the operating surgeon. this trial will also be used to assess the feasibility of recruitment to a future larger study, and any data collected will be used as pilot data.

this study has been designed to assess the ergonomics of versius® assisted surgery in comparison with laparoscopic surgery in the management of abdominal hernias. the study will randomise 60 patients who require repair of an abdominal hernia and have been deemed suitable for a minimally invasive approach. patients will be randomised to receive either laparoscopic or versius® robotic assisted surgery but will be informed that it will be attempted via a minimally invasive approach that could include either of these two subtypes of minimally invasive surgery.

Eligibility criteria:
inclusion criteria: * age ≥18 years * need for abdominal hernia repair surgery * incisional * congenital * deemed suitable for minimally invasive surgery exclusion criteria: * patients who are unable to consent * prisoners * patients in need of emergency surgery * patients with a hernial defect size of over 7cm

Keywords: ergonomics robotics versius
the effectiveness of oral acyclovir in the treatment of molluscum contagiosum in children

Conditions: Molluscum Contagiosum

Summary: the investigators will study the effectiveness of acyclovir in the treatment of molluscum contagiosum in assiut university hospital - dermatological out patient clinic the treatment group will receive acyclovir 200 mg 5 times per day the controlled group will receive local koh solution

study population: site of the study: the outpatient dermatological clinic in assiut university hospital. participants: children (2 -16) years' old attending dermatological clinic in assiut university hospital and their parents. methodology in details: 1. we will use the social media as " facebook" to invite patient to visit the clinic and follow up them due to the protective measures of covid 19. 2. diagnosis of the patient with molluscum contagiosum according to the clinical picture 3. collecting data including personal and clinical data through interviewing the patient and his or her parents 4. pictures of the lesions will be taken before and after treatment after patient consent. 5. we will randomly assigning the patient to either treatment group or controlled group according to simple random table 6. prescribing the treatment according to the patient group 7. follow up of the patient after 1 weak and each week according to the response to treatment or presence of complication inclusion criteria: children (5 -15) years old with molluscum contagiosum. exclusion criteria: 1. molluscum contagiosum with inflamed spot 2. known immune compromised children 3. molluscum lesion in the eye lid. 4. children with renal impairment.

Eligibility criteria:
inclusion criteria: * children (2 -16) years old with molluscum contagiosum. exclusion criteria: * molluscum contagiosum with inflamed spot known immune compromised children molluscum lesion in the eye lid. children with renal impairment.
investigation into an innovative, clinical slip inducing device in the chronic incomplete spinal cord population

Conditions: Spinal Cord Injuries

Summary: the objective of this project is to fully test a newly developed affordable cost variable slip inducer in the ambulatory, incomplete spinal cord population. it is a self-contained device using a moving serial plank mechanism with wheels on the underside of each plank that allow for structured slips while a person walks over the planks with a harness for safety.

all planks appear the same but can be adjusted on the underside allowing for it to be stable or can allow a slip in the forward and/or backward direction of up to 8 inches. this distance was determined from a review of slip bio-mechanics that noted that a slip is likely to occur when a slip distance exceeds 10 cm (3.9 inches) with the probability of recovery decreasing as the distance increases. the first goal of the project is to determine the optimal distance required for individuals with incomplete spinal cord injuries to have a 50% fall rate, as healthy individuals were found to have a fall rate of 50% at 11 inches. investigators will then look at common clinical assessments and examine their ability to predict an individual's ability to recover from the individual's identified optimal slip distance. investigators will also look at within session training effect on a person's balance control following a training session using the device.

Eligibility criteria:
inclusion criteria: * diagnosed with a traumatic or non-traumatic incomplete spinal cord injury at least 6 months ago * between the ages of 18-85 years old. * ambulates as their primary means of mobility * able to walk without cane/crutch/walker for 30 feet. * weight less than 275 lbs. * medical clearance from physician exclusion criteria: * uses a wheelchair as primary means of mobility * recent (\<6 months) lower extremity fracture * other neurological diagnoses that would impact balance such as peripheral neuropathy, stroke, brain injury, etc. * lower extremity amputation * currently pregnant * uses knee-ankle-foot-orthosis for mobility.
evaluation of losartan and perindopril in blacks type 2 diabetics patients

Conditions: Type 2 Diabetes Mellitus

Summary: the aim of this study is to compare the short-term effects of acei and angiotensin ii receptor blockers on cardiac and renal protection in black type 2 diabetics patients care-plp is a double-arm, double-blind, randomized and parallel clinical trial conducted at the national obesity center in the yaoundé central hospital. a population of type 2 diabetes patients, with hypertension and / or microalbuminuria and who are not taking acei or angiotensin receptors blockers, is randomize into two groups. depending on the group, 10 mg perindopril or 100 mg losartan is add to the usual treatment for each patient. the patients are followed-up for a period of 08 weeks. the primary outcome is the variation of exercise induced urinary albumin excretion after 08 weeks of intervention.

given the particularity of the renin-angiotensin system in black subjects, the care-plp study fulfills this objective with the comparison of losartan and perindopril after 08 weeks of administration in a subsaharan african population. aim: the aim of this study is to compare the short-term effects of acei and angiotensin ii receptor blockers on cardiac and renal protection in black type 2 diabetics patients methods: care-plp is a double-arm, double-blind, randomized and parallel clinical trial conducted at the national obesity center in the yaoundé central hospital. a population of type 2 diabetes patients, with hypertension and / or microalbuminuria and who are not taking acei or angiotensin receptors blockers, is randomize into two groups. depending on the group, 10 mg perindopril or 100 mg losartan is add to the usual treatment for each patient. the patients are followed-up for a period of 08 weeks. the primary outcome is the variation of exercise induced urinary albumin excretion after 08 weeks of intervention. progress: recruitment for care-plp was completed in february 2018 with 29 patients.

Eligibility criteria:
inclusion criteria: * type 2 diabetics subjects * urinary albumin excretion \>30 g/day or blood pressure \> 140/90 * on a stable antidiabetic and antihypertensive therapies (determined by the investigator) for at least 3 months with no classes changes. the pharmacological treatment should not include an angiotensin-converting enzyme inhibitor or angiotensin ii receptor blocker * subject must not present any contraindication to exercise * before any study-specific procedure, the appropriate written informed consent must be obtained. exclusion criteria: * side effects affecting life quality of patients (determined by the data safety monitoring board). * signs of exercise intolerance * out of sight. * withdrawal of consent

Keywords: angiotensin converting enzymes inhibitor angiotensin ii receptor blockers type 2 diabetes exercise induced urinary albumin excretion blood pressure